Carregant...
Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma
Proteasome inhibitor bortezomib is an effective therapy for relapsed and newly diagnosed multiple myeloma (MM); however, dose-limiting toxicities and the development of resistance can limit its long-term utility. Recent research has focused on targeting ubiquitin receptors upstream of 20S proteasome...
Guardat en:
| Publicat a: | Leukemia |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5749253/ https://ncbi.nlm.nih.gov/pubmed/27118409 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2016.97 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|